Drugs / Eutropin
Eutropin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03154840 | May → Jul 2017 | — | LG Chem | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02204163 | Jun 2014 → Dec 2017 | Prader-Willi syndrome | LG Life Sciences | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02693522 Comparator | Oct 2003 → Dec 2004 | pituitary deficiency | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eutropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03154840 ↗ |
| Known as | Eutropin AQ | “Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU” NCT03154840 ↗ |
| Known as | Eutropin Pen | “Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU” NCT03154840 ↗ |
| Known as | rhGH | “the safety of rhGH (Eutropin, LG Chem, Ltd.) and its efficacy” PMID 31511031 ↗ Sep 2019 |
| Modality | Protein / enzyme biologic | “Recombinant human growth hormone (rhGH) treatment improves the symptoms” PMID 31511031 ↗ Sep 2019 |
| Route | Subcutaneous | “Subcutaneous injection” NCT02693522 ↗ |